Neumora Therapeutics is a clinical-stage biotechnology company focused on developing neuroscience drugs.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/11/2022 | Series B | $112.4MM | $xx.xx | $1.33B | Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
74,930,001
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners
|
||||||
10/07/2021 | Series A-1 | $31.84MM | $xx.xx | $909.09MM | Alexandria Venture Investments, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, Re.Mind Capital, Softbank, Surveyor Capital, Waycross Ventures | |
Price per Share
$xx.xx
Shares Outstanding
31,841,938
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, Re.Mind Capital, Softbank, Surveyor Capital, Waycross Ventures
|
||||||
10/07/2021 | Series A-2 | $468.16MM | $xx.xx | $909.09MM | Alexandria Venture Investments, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, Re.Mind Capital, Softbank, Surveyor Capital, Waycross Ventures | |
Price per Share
$xx.xx
Shares Outstanding
468,158,062
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, Re.Mind Capital, Softbank, Surveyor Capital, Waycross Ventures
|